Targeting the Hepatic BMP-SMAD Pathway in Leptin Receptor Deficiency (LEPRD) (THOLD)
Targeting the Hepatic BMP-SMAD Pathway in Leptin Receptor Deficiency (LEPRD): A New Strategy for Treating Severe Genetic Obesity or Leptin Deficiency
The goal of this observational study is to learn more about the role of TMPRSS6 in patients with leptin receptor deficiency (LEPRD) or genetic lipodystrophy associated with leptin deficiency. LEPRD is a rare genetic condition that causes severe obesity and excessive hunger, while genetic lipodystrophy is characterized by a loss of body fat and can be associated with severe metabolic problems.
The main questions it aims to answer are:
Is TMPRSS6 associated with metabolic and liver health in patients with LEPRD or genetic lipodystrophy? Are differences in TMPRSS6 levels or activity associated with blood sugar control, lipid levels, body fat, or liver health?
Participants will:
Provide a blood sample for the measurement of TMPRSS6 and other metabolic and molecular markers.
Have information from their clinical and laboratory assessments collected for the study.
This study may help researchers better understand the mechanisms underlying metabolic complications in LEPRD and genetic lipodystrophy and may contribute to the identification of new potential therapeutic targets in the future.
調査の概要
状態
詳細な説明
Leptin receptor deficiency (LEPRD) is an extremely rare autosomal recessive endocrine disorder characterized by severe early-onset obesity, hyperphagia, and metabolic abnormalities resulting from impaired leptin signaling. Genetic forms of lipodystrophy, including generalized and partial lipodystrophy, may also be associated with severe leptin deficiency and impaired leptin signaling, leading to abnormalities in glucose and lipid metabolism and ectopic fat accumulation, particularly in the liver.
Current therapeutic approaches do not fully address the metabolic complications associated with these rare disorders. In patients with LEPRD, setmelanotide, a selective melanocortin-4 receptor (MC4R) agonist, acts downstream of the leptin-melanocortin pathway and can substantially reduce hunger and body weight. However, the response to treatment may be limited in some patients, and metabolic and hepatic abnormalities may persist. Similarly, metreleptin replacement therapy used in selected forms of genetic lipodystrophy may not completely correct all metabolic and hepatic abnormalities. Therefore, identification of additional molecular pathways involved in the metabolic complications of these conditions is needed.
TMPRSS6 is a type II transmembrane serine protease predominantly expressed in hepatocytes. It negatively regulates hepatic BMP-SMAD signaling by cleaving hemojuvelin (HJV), a coreceptor of the BMP pathway, thereby contributing to the regulation of hepcidin production. Preclinical studies have shown that genetic inactivation or antisense oligonucleotide-mediated silencing of Tmprss6 in mice results in activation of the hepatic BMP-SMAD pathway and is associated with beneficial metabolic effects, including improved glucose metabolism, reduced adipose tissue accumulation, and attenuation of inflammation.
Preliminary studies in murine models have identified circulating liver-derived factors, including TMPRSS6-related molecular markers, that may be involved in the metabolic alterations associated with impaired leptin signaling. These findings suggest that TMPRSS6 and the hepatic BMP-SMAD pathway may play a role in the interaction between hepatic function and systemic glucose and lipid metabolism.
The present pilot observational study is designed to investigate whether molecular alterations identified in preclinical models are also detectable in humans with LEPRD or genetic lipodystrophy associated with leptin deficiency. Blood samples will be collected to measure circulating TMPRSS6 and other molecular or metabolic markers previously identified in preclinical studies as being regulated by or associated with TMPRSS6 activity.
The study will integrate these molecular findings with available clinical and biochemical characteristics of the participants. Particular attention will be given to markers of glucose and lipid metabolism and hepatic involvement, in order to explore potential associations between TMPRSS6-related markers and the metabolic phenotype of these rare disorders.
The study is intended to provide preliminary evidence regarding the relevance of the TMPRSS6-related pathway in humans. Identification of a specific circulating molecular signature associated with TMPRSS6 may improve understanding of the mechanisms underlying metabolic and hepatic complications in LEPRD and genetic lipodystrophy and provide a rationale for future translational studies investigating this pathway as a potential therapeutic target.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Flavia Prodam, MD, PhD
- 電話番号:+39-0321-660693
- メール:flavia.prodam@med.uniupo.it
研究場所
-
-
Italy
-
Novara、Italy、イタリア、28100
- 募集
- AOU Maggiore della Carità - SCDU Endocrinology
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will include pediatric and adult patients of both sexes with leptin receptor deficiency (LEPRD) or genetically determined leptin deficiency associated with generalized or partial lipodystrophy. Approximately 35 patients with genetic lipodystrophy and up to 10 patients with LEPRD will be enrolled. Participants may be untreated or receiving setmelanotide or metreleptin.
説明
Inclusion Criteria:
- Male or female participants aged 0 to 99 years.
- Diagnosis of leptin receptor deficiency (LEPRD) or genetically determined leptin deficiency associated with generalized or partial lipodystrophy.
- Participants may be untreated or receiving treatment with setmelanotide or metreleptin.
- Ability and willingness to provide written informed consent. For participants under the legal age, informed consent will be obtained from the parent(s) or legal guardian(s), together with assent from the minor when appropriate.
Exclusion Criteria:
- Diagnosis of another form of genetic obesity.
- Pregnancy or planned pregnancy during the study participation period.
- Liver disease or hepatic impairment attributable to other causes, including excessive alcohol consumption.
- Genetically determined dyslipidemia due to another cause.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Circulating Hepatokine Levels
時間枠:At study enrollment
|
Measurement of circulating hepatokines, including TMPRSS6, in serum and plasma using immunoenzymatic assays such as ELISA or multiplex assays, and assessment of their association with clinical and biochemical parameters related to glucose metabolism, lipid metabolism, and liver health. |
At study enrollment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CE073/2026
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。